enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Enfortumab vedotin - Wikipedia

   en.wikipedia.org/wiki/Enfortumab_vedotin

   Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate [6] used for the treatment of urothelial cancer. [4] [7] It is a nectin-4-directed antibody and microtubule inhibitor conjugate. [4] [7] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. [5]

3. Bladder cancer - Wikipedia

   en.wikipedia.org/wiki/Bladder_cancer

   Those whose tumors continue to grow after platinum chemotherapy and immune checkpoint inhibitors can receive the antibody drug conjugate enfortumab vedotin ("Padcev", targets tumor cells with the protein nectin-4). [32] [33] Enfortumab vedotin in combination with pembrolizumab can also be used as a first-line therapy in place of chemotherapy. [32]

4. List of antineoplastic agents - Wikipedia

   en.wikipedia.org/wiki/List_of_antineoplastic_agents

   Bladder, breast, nasopharyngeal, non-small cell lung, ovarian and pancreatic cancer, lymphomas and inflammatory bowel disease. Myelosuppression, pulmonary toxicity, kidney failure (rare), haemolytic uraemic syndrome (rare), thrombotic thrombocytopenic purpura (rare), anaphylactoid reaction (rare), reversible posterior leucoencephalopathy ...

5. Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review

   www.aol.com/news/seattle-genetics-enfortumab...

   The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.

6. Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA ... - AOL

   www.aol.com/news/seagens-sgen-maa-enfortumab...

   The European Medicines Agency accepts Seagen (SGEN) and Astellas Pharma's marketing application for enfortumab vedotin for treating adult patients with advanced/metastatic urothelial cancer.

7. Seattle Genetics, Astellas drug rapidly shrinks tumors in ...

   www.aol.com/news/seattle-genetics-astellas-drug...

   Seattle Genetics shares rose 4.3% to $67.84. Responses were similar even among patients with the worst prognosis, including those whose cancer had spread to the liver, patients who had received ...